<DOC>
	<DOCNO>NCT01059786</DOCNO>
	<brief_summary>Background : - Researchers attempt develop new treatment hairy cell leukemia ( HCL ) respond well recur standard HCL therapy . One nonstandard treatment HCL rituximab , antibody bind cancer cell help immune system destroy . By combine rituximab anti-cancer drug , researcher hope determine whether combined drug successful treat HCL . - Pentostatin bendamustine two anti-cancer drug use treat different kind blood immune system cancer . Bendamustine approve treat kind leukemia lymphoma , use treat HCL . Pentostatin use 20 year treat HCL , combine rituximab official clinical trial . Objectives : - To determine whether rituximab either pentostatin bendamustine effective treatment HCL rituximab alone . - To determine whether pentostatin bendamustine effective treatment HCL combine rituximab . Eligibility : - Individuals least 18 year age diagnose hairy cell leukemia respond well relapse standard HCL therapy . Design : - The study last four treatment cycle 28 day . - Prior study , participant screen full medical history physical exam , bone marrow biopsy ( one perform last 6 month ) , compute tomography ( CT ) ultrasound scan , tumor measurement , test require researcher . Participants provide blood urine sample time well . - Rituximab bendamustine : Participants receive rituximab Days 1 15 cycle bendamustine Days 1 2 cycle , total four cycle . - Rituximab pentostatin : Participants receive rituximab Days 1 15 cycle pentostatin rituximab Days 1 15 cycle , total four cycle . - Participants regular test treatment cycle , include bone marrow biopsy CT ultrasound scan . Participants also provide regular blood urine sample assess result treatment .</brief_summary>
	<brief_title>Randomized Phase II Trial Rituximab With Either Pentostatin Bendamustine Multiply Relapsed Refractory Hairy Cell Leukemia</brief_title>
	<detailed_description>Background : - Hairy cell leukemia ( HCL ) highly responsive purine analog cladribine pentostatin , without evidence cure . Neither standard 2 course , due cumulative marrow T-cell toxicity decline remission rate duration . Once resistant , patient multiple relapse die disease-related cytopenia . - Rituximab alone 51 patient 5 trial cytopenias least 1 prior purine analog result 10 complete + 10 partial remission ( CR+PR= ORR 39 % ) . - Rituximab cladribine give high CR rate 1st 2nd line , standard . - While cladribine use common 1st 2nd line , pentostatin often use subsequent treatment &lt; 100 % cross-resistance . - Retrospective publish data pentostatin plus rituximab HCL include 7 7 response 6 ( 86 % ) CRs , prospective data . - Recombinant immunotoxins target CD25 ( LMB-2 ) CD22 ( BL22 HA22 ) highly active purine analog resistant HCL . Palliative pentostatin-rituximab often use off-protocol patient immunogenicity need therapy . - Bendamustine approve early treatment CLL , effective rituximab relapsed/refractory CLL . Its use HCL unreported . - CRs minimal residual disease ( MRD ) immunohistochemistry bone marrow biopsy ( BMBx IHC ) , relapse early . Tests HCL MRD blood marrow include flow cytometry ( FACS ) PCR use consensus primer . The sensitive MRD test HCL real-time quantitative PCR use sequence-specific primer ( RQ-PCR ) . - Of 5 HCL-specific trial list Cancer.gov , 2 phase II trial cladribine + rituximab 1st 2nd line ( 1 randomize NIH , 1 non-randomized MDA ) , 3 NIH phase I-II trial recombinant immunotoxins BL22 , HA22 LMB-2 . Objectives : -Primary : -- To determine pentostatin + rituximab bendamustine + rituximab associate adequate response rate ( ORR=PR+CR ) patient relapse HCL , , , select combination likely superior . Eligibility : - HCL need therapy , either &gt; 2 prior course purine analog , 1 course purine analog plus &gt; 1 course rituximab &lt; 1 year response 1 course purine analog , diagnosis HCL variant ( HCLv ) , unmutated IGHV4-34+expressing HCL/HCLv . - Prior treatment , ineligibility , patient refusal recombinant immunotoxin . Design : - Rituximab 375 mg/m ( 2 ) day 1 , 15 6 x 28-day cycle ( 68 patient ) . - Randomize : 1 ) 28 patient bendamustine 90 mg/m2/day , day 1 2 cycle 2 ) 28 patient pentostatin 4 mg/m2 day 1 15 cycle . Initial tolerability study : 12 patient receive rituximab + bendamustine ( nonrandom ) , include 6 70 mg/ ( 2 ) 6 90 mg/ ( 2 ) bendamustine . - Statistics : If &gt; 14/28 respond , conclude 90 % power response &gt; 40 % arm . &gt; 80 % probability select good arm true response probability approximately 40-50 % inferior arm &gt; 15 % high superior arm . - Stratify equalize % patients/arm refractory last course purine analog . - Accrual Ceiling : 74 , include 0-6 nonrandomized patients/arm prior noresponse regimen . Allow crossover failure either regimen .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>INCLUSION CRITERIA : 2.1.1.1 . Evidence HCL flow cytometry blood , confirm Laboratory Pathology , NCI , include positivity CD19 , CD22 , CD20 , CD11c . Patients flow cytometry consistent HCL variant ( HCLv ) eligible , include CD25 and/or CD103 negative disease . 2.1.1.2.BMBx BMA consistent HCL , confirm NIH Laboratory Pathology , NCI , Department Laboratory Medicine , Clinical Center , NIH . 2.1.1.3 . Treatment indicate base demonstration least one follow 4 week time enrollment , less 6 month prior cladribine less 4 week prior treatment , applicable . Neutropenia ( ANC le 1000 cells/microl ) . Anemia ( Hgb less 10g/dL ) . Thrombocytopenia ( Plt less 100,000/microl ) . Absolute lymphocyte count ( ALC ) great 5,000 cells/microL Symptomatic splenomegaly . Enlarging lymph node great 2cm . Repeated infection require oral i.v . antibiotic . Patients eligible blood count within 4 week enrollment consider ineligible subsequent blood count prior enrollment fluctuate become ineligible time enrollment . 2.1.1.4 . One following : At least 2 prior course purine analog 1 prior course purine analog plus great equal to1 course rituximab response course purine analog last less 1 year . Diagnosis HCL variant ( HCLv ) Unmutated ( &gt; 98 % homology germline ) IGHV434+expressing HCL/HCLv 2.1.1.5 . ECOG performance status ( 100 ) 03 2.1.1.6 . Patients must able understand give informed consent . 2.1.1.7 . Creatinine le equal 1.5 creatinine clearance great equal 60 ml/ml . 2.1.1.8 . Bilirubin le equal 2 unless consistent Gilbert ( total/direct great 5 ) , ALT AST less equal 3 x upper limit normal . 2.1.1.9 . No therapy ( i.e . chemotherapy , interferon ) 4 week prior study entry , cladribine 6 month prior study entry , unless progressive disease 2 month cladribine document . 2.1.1.10 . Age least 18 2.1.1.11 . Men woman reproductive potential must agree use acceptable method birth control treatment twelve month completion treatment . EXCLUSION CRITERIA : 2.1.2.1 . Presence active untreated infection 2.1.2.2 . Uncontrolled coronary disease NYHA class IIIIV heart disease . 2.1.2.3 . Known infection HIV , hepatitis B C. 2.1.2.4 . Pregnant lactating woman . 2.1.2.5 . Presence active 2nd malignancy require treatment . 2nd malignancy low activity require treatment ( i.e . low grade prostate cancer , basal cell squamous cell skin cancer ) constitute exclusion . 2.1.2.6 . Inability comply study and/or followup procedure . 2.1.2.7 . Presence CNS disease 2.1.2.8 . Patients history nonresponse pentostatin plus rituximab bendamustine plus rituximab . 2.1.2.9 . Receipt live vaccine within 4 week prior randomization . Efficacy and/or safety immunization period Bcell depletion adequately study . It recommend patient vaccination record possible requirement review . The patient may require vaccination/booster administer least 4 week prior initiation study treatment . Review patient immunization status follow vaccination recommend : tetanus ; diphtheria ; influenza ; Pneumococcal polysaccharide ; Varicella ; measles , mumps rubella ( MMR ) ; hepatitis B . Patients consider high risk hepatitis B virus ( HBV ) infection investigator determine immunization indicate complete entire HBV vaccine series least 4 week prior participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 21, 2017</verification_date>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Purine Analog</keyword>
	<keyword>Soluble CD25</keyword>
	<keyword>Minimal Residual Disease MRD</keyword>
	<keyword>CD20</keyword>
	<keyword>Hairy Cell Leukemia</keyword>
</DOC>